Pe­ter Thiel-backed ATAI is prepar­ing to go to Nas­daq, as in­ter­est in psy­che­delics reach­es fever pitch

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The team be­hind ATAI Life Sci­ences has ratch­eted up mo­men­tum over the last few months, and now they’re look­ing to cap­i­tal­ize with an IPO.

Backed by bil­lion­aire Pe­ter Thiel, ATAI filed its SEC pa­per­work late Tues­day and out­lined its plans to take its port­fo­lio of ex­per­i­men­tal psy­che­del­ic med­i­cines to Nas­daq. They’ve list­ed a $100 mil­lion raise for now, though that fig­ure has com­mon­ly proved to be a mere place­hold­er dur­ing the biotech boom and the com­pa­ny could end up rais­ing much more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.